What High-Performing MedTech Teams Measure Before Entering a New Hospital System

Entering a new hospital system is rarely a straightforward commercial exercise. Even when the clinical use case is clear, adoption often depends on a more complicated mix of factors like where the relevant patients are being treated, where the associated procedures are actually being performed, how much autonomy individual hospitals have within the broader system, and which internal stakeholders influence product evaluation.

In many systems, physician interest is only one part of the process. Product review may also involve value analysis leaders, sourcing and procurement teams, finance, nursing, clinical operations, and service-line leadership, each evaluating the proposal through a different lens.

AHRMM describes the supply chain’s role as helping connect clinicians with quality products in a cost-effective manner and as supporting decision-making alongside stakeholders such as finance and infection control, while ECRI describes value analysis as a structured process that weighs quality, safety, efficacy, and cost rather than price alone.

The broader market dynamics also matter because hospital spending in the United States grew 8.9% to $1.6347 trillion in 2024, accounting for 31% of total national health expenditures, according to CMS. That level of spending tells you hospitals remain central to device commercialization, but it does not mean hospitals are easy buyers. They are under constant pressure to manage cost, staffing, operational complexity, and quality performance at the same time.

Moreover, the American Hospital Association reports that 67% of AHA member hospitals are part of health systems, and most of those systems comprise 3 to 10 hospitals. That creates a familiar challenge for medical device market planning. One account may actually be a network of sites with different patient mixes, different procedural concentrations, different internal champions, and different degrees of local autonomy.

For MedTech companies, that makes broad hospital lists and specialty-based targeting less reliable on their own. Before commercial teams spend heavily on a target system, they need a clearer read on where the relevant patient burden sits, where the related procedures are actually being performed, which physicians have influence, and how product decisions move through the organization.

Without that, a launch plan can look active on paper while drifting through the wrong accounts in the real market.

Understanding the Role of Value Analysis Committees (VACs)

Before a hospital system adopts a new device, there is usually a review layer between physician interest and institutional action. In many cases, that layer is often the Value Analysis Committee (VAC).

In many hospitals and health systems, VACs are responsible for reviewing and standardizing products considered important to patient care, with input from clinicians, supply chain, administrators, and often finance or quality stakeholders.

Vacs Matter Before The First Serious Push

A 2024 review describes the primary role of a Value Analysis Committee as adopting and standardizing products considered important to patient care. It also notes that these committees typically bring together clinicians, supply chain staff, and administrative stakeholders.

That mix matters because a hospital does not evaluate a new device only through a clinical lens. It also looks at purchasing impact, workflow implications, implementation burden, and whether the product is worth introducing into an already complex operating environment.

That makes the VAC central to hospital adoption strategy for medical devices. Even when a physician sees clear value, the institution may still ask harder questions, such as whether the product creates additional cost, whether it requires staff retraining, whether it replaces something already under contract, and whether the clinical benefit will be strong enough, visible enough, and repeatable enough to justify standardization.

Hospitals Are Evaluating Devices Under Financial Pressure

This review process has become even more important because hospitals are not making adoption decisions in a financially relaxed setting. CMS data show hospital spending continues to rise, but that increase does not mean greater flexibility. It often reflects the opposite, that higher input costs, tighter margins, and a stronger need to justify any new product that adds expense or operational complexity.

That is one reason value analysis has become so influential. Hospitals are not simply asking whether a device works. They are asking whether it works well enough, for the right patients, in the right setting, without creating friction that outweighs the benefit.

For MedTech companies, that changes how hospital entry should be planned. A field team should not treat physician enthusiasm as proof that the account is commercially ready. The better approach is to ask much earlier whether the hospital system is likely to see the product as clinically relevant, economically defensible, and practical to implement.

Weak Targeting Makes VAC Approval Harder

In most systems, VAC review is a structured evaluation process involving multiple stakeholders and multiple approval layers.

AHRMM’s cost, quality, and outcomes framework reflects this broader logic by positioning supply chain decisions at the intersection of clinical performance, financial impact, and organizational results rather than product price alone.

ECRI similarly describes value analysis as a workflow that often spans several levels of approval across a health system and is designed to support informed decisions on new products.

That process becomes harder when the commercial team cannot show why the product belongs in that account in the first place. If the target system has thin indication density, limited relevant procedure activity, or a weak fit with existing workflows, the case has to work much harder under review.

The committee is not only asking whether the product is clinically sound. It also asks whether the hospital is likely to use it often enough, whether implementation is practical, and whether the value justifies the operational and financial costs of adoption.

That is why better targeting and VAC readiness are closely connected. Stronger account selection gives the team a more credible clinical and operational case before formal review begins.

Measuring Clinical Indication Density Before Hospital Entry

If a hospital system is not seeing enough of the right patients, the rest of the opportunity can be overstated very quickly. That is why one of the most useful measures before hospital entry is clinical indication density.

A Large Health System Can Still Be A Weak Fit

A large health system can still be a weak fit for a specific device. For example, a flagship academic hospital may look attractive because of scale and brand visibility, but the relevant procedures may be spread thinly across multiple sites, or the target condition may not be concentrated there at a meaningful level.

A smaller regional system may be a better fit if it treats a larger share of the relevant patient population in a more concentrated procedural setting. In another case, a system may have a strong service-line reputation overall while referring a meaningful share of the relevant work elsewhere, which weakens the practical case for entry.

That is the value of diagnosis-level analysis. It helps separate broad presence from real relevance. For clinical data for device commercialization, this is a major shift. Instead of targeting hospitals because they appear active in a broad specialty category, teams can look more closely at where the concentration of the target condition is actually showing up.

That makes hospital selection more specific and reduces the risk of chasing accounts that look promising only from a distance.

ICD-10 Data Helps Separate Broad Presence From Real Demand

ICD-10 is the standardized coding system used in the United States to code and classify medical diagnoses and conditions. Because it captures diagnosis information, it gives MedTech teams a way to assess where patient need is concentrated before they treat a hospital system as a serious commercial target.

That is why ICD-10 targeting in medical device sales can be so useful at the front end. Diagnostic data helps answer a basic but often neglected question, which is whether a system is seeing enough of the right patients to sustain product relevance.

That question sounds simple. It is not. Many targeting models still lean too heavily on specialty labels, physician lists, or hospital category tags. Those signals can be directionally helpful, but they are not precise enough for hospital entry planning on their own.

A 2023 study found that NPI taxonomy is not accurate for describing a surgeon’s subspecialty or actual clinical practice, which directly supports the point that specialty labels alone are too blunt for precise targeting.

In other words, broad specialty labels may describe the general field, but they do not reliably tell you what procedures a physician actually performs or how specialized their day-to-day practice really is.

Diagnosis Data Works Best When Paired With Procedure Activity

Diagnosis density is not the whole story. A hospital may see a large number of relevant patients and still not be an ideal entry point if the related procedures are being referred elsewhere, if the cases are fragmented across too many facilities, or if the institutional path to adoption is unusually difficult.

Still, it is a strong first filter. It helps teams narrow the market before they spend time on deeper account work. It also gives commercial and medical teams a shared starting point.

If the account does not show a meaningful concentration of the relevant condition, there is a good chance the opportunity has been overstated.

Diagnostic data help establish whether the patient burden exists. Procedure data helps confirm whether the hospital system is actually doing the related clinical work. Used together, they create a much more reliable picture than broad specialty targeting alone.

What Indication Density Helps Teams Avoid

Strong indication analysis does not just help identify promising accounts. It also helps teams avoid weak ones.

It reduces the odds of entering hospital systems where the clinical need is too thin, too scattered, or too inconsistent to support adoption. It helps prevent situations in which a field team gets early interest from one physician but cannot build broader momentum because the underlying patient volume is lacking.

And it makes account prioritization more defensible internally, which matters when commercial resources are limited, and leadership wants to know why one system is being pursued over another.

That is the practical value of measuring indication density before hospital entry. It makes the targeting sharper, the internal case stronger, and the downstream work less dependent on guesswork.

Identifying Clinical Champions Within the Hospital System

Clinical champions matter because VAC review and broader hospital adoption rarely move on product evidence alone. They move when someone within the institution can connect that evidence to a real clinical problem, explain where the product fits in practice, and help the case advance through the review process.

In that sense, champion identification is not separate from VAC readiness. It is part of it. The most useful champions help shape the internal case before formal review begins and support it as the account moves through the evaluation process.

In a hospital system, a supportive physician can open a conversation, but that does not automatically create institutional traction. The stronger question is whether that physician has enough credibility, procedural relevance, and internal reach to influence broader adoption.

One Supportive Physician Is Not the Same as a True Champion

Clinical champions matter because hospital product decisions are rarely made by one stakeholder in isolation. A surgeon or service-line physician may spot the value of a device early, but broader adoption still depends on whether that value can travel beyond the individual user.

That distinction shows up in implementation research, too. A 2024 systematic mixed-methods review on champions in healthcare technology implementation found that champions can play an important role in supporting adoption, but their impact depends heavily on context, expertise, and the extent to which their role is anchored within the organization.

The review screened 1,629 studies and included 23 in the final analysis, lending the finding more weight than the usual anecdotal “champions are helpful” line repeated in launch planning.

For MedTech teams, that means a champion should not be treated as a personality trait. It should be treated as a functional role inside the account.

A physician may be enthusiastic and still have limited influence over committee review, purchasing norms, or broader service-line behavior. Another may have less visible enthusiasm but far stronger internal credibility. If the account plan does not distinguish between those two profiles, the team can easily overestimate how much momentum it really has.

The Best Champions Sit Close to the Clinical Use Case

Not every influential physician is the right champion for a specific product. In hospital entry, the most useful champions tend to be closely tied to the actual procedure mix, patient population, and care setting relevant to the device.

That is important because internal influence is much more persuasive when it is grounded in real practice. A physician who is actively performing the related procedures, seeing the relevant patient types, and working within the specific service line where the product would be used is in a stronger position to make the case than someone with a broader title but thinner day-to-day relevance.

This is one reason procedure-level targeting matters so much in early account planning.

Platforms like Alpha Sophia are useful here because they focus on identifying surgeons not only by specialty but also by the volume and frequency of procedures they actually perform, along with the hospitals and ASCs where that activity occurs. That is a far better basis for champion identification than a broad specialty roster.

Champion Quality Depends on More Than Clinical Enthusiasm

A 2024 systematic mixed-studies review on champions in healthcare technology implementation found that champions can support implementation, but their impact depends heavily on context, expertise, role clarity, and the extent to which the role is anchored within the organization.

The review screened 1,629 studies and included 23. So, a true clinical champion usually does three things well.

First, they connect the product to a visible problem the institution already cares about. That could be procedure efficiency, patient outcomes, workflow burden, complication reduction, or a gap in current treatment options.

Second, they can explain the product in a way that makes sense to peers, not just to vendor-facing stakeholders.

Third, they can help the commercial team understand how the account actually works, including where resistance is likely to come from.

That last point is easy to miss, but it matters a lot. A good champion knows which objections are likely to matter. They know whether value analysis will focus more heavily on economics, standardization, or operational burden. They know which other clinicians may need to be brought along. They know whether the account tends to move cautiously or can accommodate pilot use when the case is strong enough.

That makes champion identification part of medical device market planning, not only of field relationship-building. The earlier a team can tell the difference between a genuine internal sponsor and a friendly but isolated user, the better its entry strategy tends to be.

Clinical Champions Are Stronger When They Are Not Working Alone

The same 2024 review found limited evidence that having multiple champions may support implementation more effectively in some settings. That tracks with how hospital adoption often works in real life.

A physician champion may help create urgency, but broader uptake usually gets stronger when support is echoed by others in the account, whether that means nursing leadership, department administrators, or additional physicians within the same service line.

For MedTech teams, that is useful because it changes the goal. Instead of asking whether there is a single physician who might help, teams can ask whether there is a credible internal base to support the movement. That is a better sign that the product has room to travel beyond individual preference and toward institutional use.

Evaluating Institutional Structure and Decision Pathways

A hospital system can look unified from the outside and behave very differently on the inside. That gap is one of the main reasons account plans that seem sensible in a spreadsheet start to fall apart once field activity begins.

Health system research shows that systems vary widely in governance complexity, ownership structure, and degree of structural, functional, and clinical integration. Some have centralized business functions and more coordinated contracting. Others remain much more uneven in how authority and implementation actually work across sites.

That matters for MedTech because a system-affiliated account is not automatically a single buying environment. Review authority, physician influence, procurement control, and procedural activity may sit in different parts of the system.

ECRI’s value analysis workflow materials also reflect that product review can involve multiple levels of approval across a health system, which helps explain why a single successful conversation does not automatically translate into enterprise-wide traction.

For example, a flagship hospital may carry the system brand and house the most visible leadership, while the highest concentration of relevant procedures sits at another hospital or outpatient site.

In another system, local clinicians may support evaluation at one facility, but contracting or value analysis authority may sit centrally, which changes where the real decision path runs. In a more decentralized structure, one site may be a workable entry point without creating immediate access to the rest of the system.

A Hospital System Is Not Always a Single Buying Environment

This is becoming more important because system affiliation is now the norm rather than the exception.

That means a MedTech company is often not walking into a single hospital with a clear decision path. It is entering a connected environment where authority, influence, and operational control may sit in different places.

That structure affects almost everything. It changes where the review starts. It changes where procurement authority sits. It determines whether a successful evaluation can spread to other sites or remain confined to a single facility. It even changes how a clinical champion should be evaluated, because a physician with strong local influence may still have limited reach across a broader system.

So before entering a new account, high-performing teams look beyond the parent brand. They ask how the system behaves.

Procedure Activity and Growth Trends Matter More Than Brand Visibility

One of the most common mistakes in hospital entry is assuming the flagship hospital is automatically the best entry point.

Relevant case volume may sit elsewhere, and year-over-year procedure trends may show that the most attractive opportunity is not the most visible site, but the one where related activity is already growing. That matters because procedure growth is often uneven across specialties, settings, and regions, which makes static account appearance a poor substitute for real utilization patterns.

That is why the procedural footprint is so important in a healthcare system expansion strategy. Alpha Sophia’s MedTech solution leans into this point by focusing on surgeon-to-facility mapping and site-of-care visibility, which helps teams see where relevant activity is actually happening rather than where it seems likely to happen.

Decision Pathways Need To Be Mapped Before Resources Are Committed

Institutional structure becomes much more useful when it is translated into decision pathways. That means understanding where product evaluation begins, who influences the process, how site-level needs interact with system-level controls, and whether the account behaves more like one enterprise pursuit or several linked but separate opportunities.

This part is not glamorous, but it is where a lot of wasted effort can be prevented.

A MedTech team may have a strong clinical case and still struggle because it assumed physician support would move the account faster than it actually can.

Another team may underestimate an account because it appears decentralized, when in fact a single well-chosen site could provide a workable entry point into the broader system. Those are very different situations, and they require different commercial motions.

Better Structure Mapping Makes Prioritization More Defensible

When teams can show that a target system has concentrated procedure activity, a credible internal champion base, and a workable path through review, the case for investment becomes much stronger.

When the system shows fragmented activity, unclear governance, or low procedural density in the relevant use case, that account may still be worth pursuing later, but it should not be mistaken for a near-term opportunity.

This is one reason better account structure mapping improves planning quality. It gives commercial teams a way to separate attractive logos from realistic launch candidates.

Aligning Commercial and Medical Affairs Strategy

Hospital entry becomes slower and messier when Commercial and Medical Affairs work from different versions of the same market.
Commercial focuses on account prioritization, access, and execution. Medical Affairs brings the scientific, clinical, and evidence-based support needed to help external stakeholders evaluate appropriate use. In hospital entry, that is important because product review is shaped not only by buyer access and physician interest, but also by the strength, relevance, and credibility of the scientific case.

One team may be focused on account potential, coverage, and launch speed. The other may be focused on evidence, clinician education, and appropriate use. Both are doing important work, but if they are not grounded in the same account logic, the hospital will feel the mismatch quickly.

That is especially risky in a hospital system, where product adoption is shaped by both scientific credibility and institutional practicality.

Hospital Entry Works Better When Commercial and Medical Affairs Start With the Same Market View

The issue is not whether Commercial and Medical Affairs have different jobs. Of course they do. The problem starts when they pursue the same account with different assumptions about where the opportunity lies and what the account needs to hear first.

Commercial may prioritize a system because it looks large or strategically important. Medical Affairs may focus on clinicians who are scientifically relevant but not central to actual device uptake. None of those moves is irrational on its own. Together, though, they can create a fragmented launch effort. That is why shared market context matters.

Medical Affairs Strengthens Hospital Entry When the Scientific Story Matches the Account

Medical Affairs plays a defined role in that process. MAPS describes Medical Affairs as one of the strategic pillars of the MedTech industry, with responsibilities that include evidence generation, scientific communication, field medical engagement, and insight development.

That means Medical Affairs helps ensure that the scientific case is accurate, relevant, and useful to external stakeholders evaluating the product. It is not limited to presenting data. It helps provide scientific context for appropriate use, evidence needs, and stakeholder questions that sit alongside the commercial motion.

That broader strategic role is reflected in the literature, too. A 2023 review on the value and deliverables of Medical Affairs describes the function as increasingly strategic across pre- and post-launch phases, with responsibilities that go well beyond reactive scientific support.

For hospital entry, that means Medical Affairs can help pressure-test whether the evidence package actually matches the kind of account being pursued. If the product story is too broad, too generic, or too disconnected from how the hospital sees the clinical problem, even a strong evidence base can land flat.

Shared Planning Reduces Mixed Signals in the Field

If Commercial is driving one prioritization model while Medical Affairs is engaging a different set of clinicians for a different reason, the account may receive mixed signals.

The sales message becomes too commercial. The scientific message becomes too detached from the actual adoption path. The field ends up stitching the two together on the fly, which is rarely where a good launch strategy should live.

Cross-function alignment is also increasingly emphasized in MedTech operating models. MedTech medical affairs modernization guidance notes that planning should start with alignment across Medical Affairs, R&D, and Commercial, with clear goals and a clear understanding of how each function contributes.

That is a useful reminder because hospital entry is one of the clearest places where disconnected planning becomes visible fast.

How Alpha Sophia Supports Hospital Entry Strategy

The earlier sections point to the same operational problem that hospital entry gets weaker when teams cannot see where the target condition is concentrated, where the related procedures are actually happening, which clinicians are closest to that activity, and how opportunity is distributed across sites of care.

Alpha Sophia is built to support exactly that kind of pre-entry analysis.

Sharper Targeting Before Outreach

For indication-level targeting, Alpha Sophia uses ICD-10 diagnosis context alongside CPT and HCPCS procedure data so teams can evaluate whether the right patient population is concentrated in the account rather than relying on broad specialty labels.

For procedural relevance, it surfaces procedure volume and frequency, which helps teams identify where the clinical work tied to adoption is actually being performed.

Better Visibility Across Sites of Care

For hospital-system navigation, Alpha Sophia maps surgeons to the hospitals and ASCs where they are active. That gives teams a better view of site-of-care concentration, procedural footprint, and which facilities may offer a more workable entry path.

And because the same diagnosis- and procedure-level logic can feed territory design, CRM, and analytics workflows, the planning model does not have to disappear once outreach begins.

Planning to Execution

Alpha Sophia also helps teams carry that logic into execution. Diagnosis- and procedure-level data can be pushed into CRM, analytics, and territory planning workflows, so reps work from the same account logic used to select the target in the first place.

Conclusion

Entering a new hospital system is rarely a sales exercise. It is a planning exercise first. The strongest MedTech teams do not rely on hospital size, brand recognition, or broad specialty filters to decide where to go. They look at diagnostic concentration, procedural activity, physician influence, institutional structure, and approval pathways before committing real resources.

That is what makes hospital entry more precise. It helps teams focus on systems where the clinical need is real, the path is workable, and the opportunity can withstand scrutiny.

FAQs

What is a Value Analysis Committee (VAC) in hospitals?
A VAC is a hospital review group that evaluates new products for clinical value, operational fit, and financial impact.

Why are VACs important for medical device adoption?
Because many hospitals review devices through committee processes, not physician preference alone.

How do MedTech companies prepare for VAC approval?
By building a case around clinical relevance, workflow fit, implementation burden, and economic impact.

What metrics indicate strong hospital market opportunity?
Useful signals include diagnosis density, procedure volume, site-of-care concentration, and physician influence.

How can clinical champions influence device adoption?
They can help shape internal opinion, support evaluation, and connect product value to real clinical use.

Why is ICD-10 data useful for hospital targeting?
It helps identify where the relevant patient burden is concentrated before outreach begins.

What challenges do MedTech companies face when entering new hospital systems?
Common hurdles include fragmented decision-making, committee review, and uneven demand across sites.

How do hospital procurement processes affect device sales?
They can slow adoption by adding scrutiny of cost, workflow, and standardization.

How can companies reduce risk before approaching a hospital system?
By checking the relevance of diagnoses, procedure activity, decision pathways, and internal champions early.

How does Alpha Sophia help identify hospital expansion opportunities?
Alpha Sophia supports this through CPT, HCPCS, and ICD-based targeting, procedure volume analysis, and surgeon-to-facility mapping.